


David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics
Berlin, Germany, 10 January 2025 – Ariceum Therapeutics (Ariceum),…

Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
License agreement centered around development of a single…

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim,…

Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production
Paris, France, 9 January 2025 – Astraveus SAS (“Astraveus”…

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
Agreement supports the research and development of up to five…

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
Former senior vice president of antibody research at Genmab…

Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Former Head of Global R&D at Bayer AG and an exceptional…

4SC announces update relating to Resminostat’s (Kinselby) Marketing Authorisation Application
Planegg-Martinsried, Germany, 7 January 2025 – 4SC AG (4SC,…

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval
Enrolment completed - 120 patients with end-stage renal disease…

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®
Barcelona, Spain and Düsseldorf, Germany – 7 January 2025 –…

Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia (FTD)
Dosing of VES001 has commenced in patients with causal gene…

Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
Financing to support the development of Orbis’…

Combination of Poolbeg and HOOKIPA Pharma Inc.
The boards of directors (each a "Board") of HOOKIPA Pharma Inc.…

European Energy and Novo Holdings announce joint venture to triple renewable energy capacity of German onshore wind parks
A partnership between Novo Holdings and European Energy will…

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
alfapump® is the first US approved active implantable medical…

TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP
TGD001 is being developed to offer patients with clotting…

Ottimo Pharma Raises over $140 Million in Series A Financing
Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital,…

Novo Holdings and SUBRA join forces to accelerate development of innovative superconductor technology for power transmission and fusion energy
Today, Novo Holdings and SUBRA announce a partnership to fast-track…

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark
A new comprehensive initiative at the Technical University of…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York